Penumbra Inc - Understand $pen stock

$PEN Market Cap: $9.559 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.164B

TTM

Gross Margin

62.9%

TTM

Net Earnings

$34.55M

TTM

Current Assets

$891.8M

Q3 2024

Current Liabilities

$153.2M

Q3 2024

Current Ratio

582.14%

Q3 2024

Total Assets

$1.479B

Q3 2024

Total Liabilities

$374.8M

Q3 2024

Book Value

$1.104B

Q3 2024

Cash

$280.5M

Q3 2024

P/E

276.7

Nov 29, 2024 EST

Free Cash Flow

$134.2M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$1.059B	$847.1M	$747.6M	$560.4M	$547.4M	$444.9M	$333.8M	$263.3M	$186.1M	$125.5M	$88.85M
YoY Change	24.95%	13.32%	33.4%	2.38%	23.03%	33.31%	26.75%	41.5%	48.27%	41.26%	21.54%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$1.059B	$847.1M	$747.6M	$560.4M	$547.4M	$444.9M	$333.8M	$263.3M	$186.1M	$125.5M	$88.85M
Cost Of Revenue	$375.9M	$311.9M	$272.2M	$222.2M	$175.4M	$152.4M	$116.6M	$92.49M	$62.04M	$42.67M	$30.97M
Gross Profit	$682.6M	$535.2M	$475.4M	$338.2M	$372.0M	$292.5M	$217.1M	$170.8M	$124.1M	$82.84M	$57.88M
Gross Profit Margin	64.49%	63.18%	63.59%	60.34%	67.95%	65.75%	65.06%	64.88%	66.66%	66.0%	65.14%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$506.5M	$449.7M	$378.3M	$287.1M	$272.7M	$226.4M	$184.3M	$148.3M	$101.9M	$64.26M	$44.92M
YoY Change	12.62%	18.87%	31.79%	5.26%	20.47%	22.82%	24.28%	45.61%	58.5%	43.06%	36.12%
% of Gross Profit	74.19%	84.03%	79.58%	84.89%	73.32%	77.39%	84.88%	86.81%	82.1%	77.57%	77.61%
Research & Development	$84.42M	$79.41M	$104.6M	$90.05M	$51.72M	$36.17M	$31.66M	$23.88M	$18.03M	$15.58M	$14.08M
YoY Change	6.32%	-24.05%	16.11%	74.1%	43.02%	14.23%	32.61%	32.44%	15.74%	10.59%	12.67%
% of Gross Profit	12.37%	14.84%	21.99%	26.63%	13.91%	12.36%	14.58%	13.98%	14.53%	18.8%	24.33%
Depreciation & Amortization	$27.26M	$24.32M	$16.41M	$12.89M	$8.104M	$6.168M	$3.781M	$2.297M	$1.752M	$751.0K	$677.0K
YoY Change	12.07%	48.23%	27.28%	59.07%	31.39%	63.13%	64.61%	31.11%	133.29%	10.93%
% of Gross Profit	3.99%	4.54%	3.45%	3.81%	2.18%	2.11%	1.74%	1.34%	1.41%	0.91%	1.17%
Operating Expenses	$609.1M	$529.1M	$482.9M	$377.1M	$324.5M	$293.4M	$216.0M	$172.2M	$119.9M	$79.83M	$59.00M
YoY Change	15.11%	9.58%	28.05%	16.23%	10.59%	35.84%	25.44%	43.63%	50.16%	35.31%	29.67%
Operating Profit	$73.55M	$6.082M	-$7.501M	-$38.94M	$47.51M	-$852.0K	$1.165M	-$1.350M	$4.179M	$3.009M	-$1.126M
YoY Change	1109.32%	-181.08%	-80.74%	-181.97%	-5676.06%	-173.13%	-186.3%	-132.3%	38.88%	-367.23%	-132.17%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$1.739M	$137.0K	$938.0K	$1.267M	$2.854M	$2.964M	$2.653M	$2.323M	$541.0K	$439.0K	$345.0K
YoY Change	1169.34%	-85.39%	-25.97%	-55.61%	-3.71%	11.72%	14.21%	329.39%	23.23%	27.25%	72.5%
% of Operating Profit	2.36%	2.25%			6.01%		227.73%		12.95%	14.59%
Other Income/Expense, Net	$6.099M	-$2.327M	-$3.939M	-$343.0K	-$227.0K	-$504.0K	-$1.342M	-$1.842M	-$696.0K	-$309.0K	-$474.0K
YoY Change	-362.1%	-40.92%	1048.4%	51.1%	-54.96%	-62.44%	-27.14%	164.66%	125.24%	-34.81%	-337.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	$79.65M	$3.892M	-$10.50M	-$38.02M	$50.14M	-$2.790M	$2.476M	-$869.0K	$4.024M	$3.139M	-$1.255M
YoY Change	1946.51%	-137.06%	-72.38%	-175.83%	-1896.95%	-212.68%	-384.93%	-121.6%	28.19%	-350.12%	-132.18%
Income Tax	-$11.30M	$5.894M	-$13.13M	-$18.76M	$3.131M	-$4.403M	-$3.611M	-$15.68M	$1.659M	$894.0K	-$5.354M
% Of Pretax Income	-14.19%	151.44%			6.25%		-145.84%		41.23%	28.48%
Net Earnings	$90.95M	-$2.002M	$5.284M	-$15.70M	$48.46M	$6.601M	$4.657M	$14.81M	$2.365M	$2.245M	$4.099M
YoY Change	-4643.16%	-137.89%	-133.65%	-132.4%	634.1%	41.74%	-68.56%	526.38%	5.35%	-45.23%	104.95%
Net Earnings / Revenue	8.59%	-0.24%	0.71%	-2.8%	8.85%	1.48%	1.4%	5.63%	1.27%	1.79%	4.61%
Basic Earnings Per Share	$2.37	-$0.05	$0.14	-$0.44	$1.39	$0.19	$0.14	$0.49	$0.09	-$0.18	$0.21
Diluted Earnings Per Share	$2.32	-$0.05	$0.14	-$0.44	$1.34	$0.18	$0.13	$0.44	$0.08	-$0.18	$0.14

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$289.2M	$188.0M	$254.9M	$264.8M	$189.4M	$200.9M	$214.6M	$128.8M	$148.8M	$51.50M	$13.70M
YoY Change	53.8%	-26.23%	-3.75%	39.81%	-5.72%	-6.38%	66.61%	-13.44%	188.93%	275.91%
Cash & Equivalents	$167.5M	$69.86M	$59.38M	$69.70M	$72.80M	$67.90M	$50.60M	$13.20M	$19.50M	$3.300M	$4.100M
Short-Term Investments	$121.7M	$118.2M	$195.5M	$195.2M	$116.6M	$133.0M	$164.0M	$115.5M	$129.3M	$48.30M	$9.500M
Other Short-Term Assets	$36.42M	$30.28M	$29.16M	$18.70M	$14.90M	$12.20M	$14.70M	$14.20M	$8.700M	$9.700M	$8.400M
YoY Change	20.29%	3.86%	55.91%	25.5%	22.13%	-17.01%	3.52%	63.22%	-10.31%	15.48%
Inventory	$388.0M	$334.0M	$263.5M	$219.5M	$153.0M	$115.7M	$94.90M	$73.00M	$56.80M	$33.50M	$27.10M
Prepaid Expenses
Receivables	$201.8M	$203.4M	$133.9M	$114.6M	$105.9M	$81.90M	$58.00M	$43.30M	$29.40M	$18.90M	$13.10M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.600M	$700.0K	$1.700M	$100.0K
Total Short-Term Assets	$915.4M	$755.7M	$681.5M	$617.7M	$463.1M	$410.7M	$382.2M	$263.8M	$244.4M	$115.3M	$62.20M
YoY Change	21.13%	10.89%	10.32%	33.38%	12.76%	7.46%	44.88%	7.94%	111.97%	85.37%
Property, Plant & Equipment	$292.5M	$291.0M	$227.1M	$127.4M	$135.5M	$35.40M	$30.90M	$21.50M	$9.000M	$5.200M	$2.000M
YoY Change	0.54%	28.13%	78.25%	-5.98%	282.77%	14.56%	43.72%	138.89%	73.08%	160.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments						$0.00	$3.900M
YoY Change						-100.0%
Other Assets	$111.0M	$77.01M	$78.68M	$58.80M	$34.30M	$33.80M	$27.70M	$23.00M	$10.50M	$900.0K	$6.900M
YoY Change	44.19%	-2.13%	33.81%	71.43%	1.48%	22.02%	20.43%	119.05%	1066.67%	-86.96%
Total Long-Term Assets	$640.9M	$615.2M	$562.8M	$205.3M	$202.8M	$104.3M	$94.50M	$44.50M	$19.40M	$6.100M	$8.900M
YoY Change	4.18%	9.31%	174.12%	1.23%	94.44%	10.37%	112.36%	129.38%	218.03%	-31.46%
Total Assets	$1.556B	$1.371B	$1.244B	$823.0M	$665.9M	$515.0M	$476.7M	$308.3M	$263.8M	$121.4M	$71.10M
YoY Change
Accounts Payable	$27.16M	$26.68M	$13.42M	$14.10M	$15.10M	$8.200M	$6.800M	$4.100M	$2.600M	$2.300M	$1.300M
YoY Change	1.78%	98.79%	-4.82%	-6.62%	84.15%	20.59%	65.85%	57.69%	13.04%	76.92%
Accrued Expenses	$114.8M	$107.2M	$108.1M	$84.60M	$65.20M	$51.60M	$39.00M	$29.90M	$23.90M	$16.60M	$13.40M
YoY Change	7.09%	-0.82%	27.73%	29.75%	26.36%	32.31%	30.43%	25.1%	43.98%	23.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.231M	$1.920M	$1.713M	$1.300M	$4.200M
YoY Change	16.2%	12.08%	31.77%	-69.05%
Total Short-Term Liabilities	$151.1M	$144.9M	$123.2M	$105.9M	$91.00M	$66.10M	$51.60M	$35.80M	$28.10M	$20.80M	$15.80M
YoY Change	4.29%	17.64%	16.33%	16.37%	37.67%	28.1%	44.13%	27.4%	35.1%	31.65%
Long-Term Debt	$23.68M	$24.87M	$26.52M	$27.10M	$26.70M	$0.00	$0.00	$0.00	$0.00	$0.00	$6.000M
YoY Change	-4.77%	-6.25%	-2.13%	1.5%						-100.0%
Other Long-Term Liabilities	$202.5M	$202.2M	$140.6M	$47.40M	$58.50M	$22.40M	$21.40M	$5.900M	$3.200M	$1.500M	$1.200M
YoY Change	0.15%	43.83%	196.63%	-18.97%	161.16%	4.67%	262.71%	84.38%	113.33%	25.0%
Total Long-Term Liabilities	$226.2M	$227.1M	$167.1M	$74.50M	$85.20M	$22.40M	$21.40M	$5.900M	$3.200M	$1.500M	$7.200M
YoY Change	-0.39%	35.88%	124.33%	-12.56%	280.36%	4.67%	262.71%	84.38%	113.33%	-79.17%
Total Liabilities	$377.4M	$372.0M	$290.3M	$181.5M	$180.0M	$92.80M	$76.30M	$41.70M	$31.30M	$22.30M	$23.00M
YoY Change	1.43%	28.14%	59.96%	0.83%	93.97%	21.63%	82.97%	33.23%	40.36%	-3.04%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding	38.40M shares	37.84M shares	36.76M shares	35.77M shares	34.75M shares	34.14M shares	32.98M shares	30.46M shares	11.99M shares	4.609M shares	4.304M shares
Diluted Shares Outstanding	39.22M shares	37.84M shares	37.88M shares	35.77M shares	36.27M shares	36.09M shares	35.32M shares	33.48M shares	14.22M shares	4.609M shares	6.501M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $9.5595 Billion

About Penumbra Inc

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 4,200 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES ABIOMED INC QuidelOrtho Corp Envista Holdings Corp GLOBUS MEDICAL INC Inspire Medical Systems, Inc. MASIMO CORP Shockwave Medical, Inc. TELEFLEX INC